Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 8/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | NDUFS8 | O00217 | 3/20 | 0.46 |
| ▸ | COXFA4 | O00483 | 3/20 | 0.46 |
| ▸ | NDUFAB1 | O14561 | 3/20 | 0.46 |
| ▸ | NDUFA1 | O15239 | 3/20 | 0.46 |
| ▸ | NDUFS4 | O43181 | 3/20 | 0.46 |
| ▸ | NDUFB5 | O43674 | 3/20 | 0.46 |
| ▸ | NDUFB3 | O43676 | 3/20 | 0.46 |
| ▸ | NDUFC1 | O43677 | 3/20 | 0.46 |
| ▸ | NDUFA2 | O43678 | 3/20 | 0.46 |
| ▸ | NDUFS5 | O43920 | 3/20 | 0.46 |
| ▸ | NDUFS7 | O75251 | 3/20 | 0.46 |
| ▸ | NDUFS2 | O75306 | 3/20 | 0.46 |
| ▸ | NDUFS6 | O75380 | 3/20 | 0.46 |
| ▸ | NDUFB1 | O75438 | 3/20 | 0.46 |
| ▸ | NDUFS3 | O75489 | 3/20 | 0.46 |
| ▸ | NDUFB6 | O95139 | 3/20 | 0.46 |
| ▸ | NDUFA3 | O95167 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13714733 | 1.00 | CYP3A4 (0.49) | CYP3A4TDP1KDM4ENDUFS8COXFA4 | |
| SCHEMBL13714667 | 1.00 | CYP3A4 (0.49) | CYP3A4TDP1KDM4ENDUFS8COXFA4 | |
| SCHEMBL13962606 | 0.97 | CYP3A4 (0.47) | CYP3A4TDP1KDM4ENDUFS8COXFA4 | |
| SCHEMBL13743063 | 0.93 | CYP3A4 (0.47) | CYP3A4TDP1KDM4ENDUFS8COXFA4 | |
| SCHEMBL13714668 | 0.92 | CYP3A4 (0.59) | CYP3A4TDP1KDM4EALDH1A1MAPT | |
| SCHEMBL13714673 | 0.92 | CYP3A4 (0.59) | CYP3A4TDP1KDM4EALDH1A1MAPT | |
| SCHEMBL13714872 | 0.92 | CYP3A4 (0.59) | CYP3A4TDP1KDM4EALDH1A1MAPT | |
| SCHEMBL14495421 | 0.90 | CYP3A4 (0.42) | CYP3A4TDP1KDM4ENDUFS8COXFA4 | |
| SCHEMBL13038655 | 0.89 | CYP3A4 (0.61) | CYP3A4TDP1KDM4EALDH1A1MAPT | |
| SCHEMBL14511465 | 0.88 | NDUFS8 (0.41) | CYP3A4NDUFS8COXFA4NDUFAB1NDUFA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576124-B2 | Anti-first-pass effect compounds | BIOAVAILABILITY SYSTEMS, L.L.C. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576124-B2 | Anti-first-pass effect compounds | BIOAVAILABILITY SYSTEMS, L.L.C. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576123-B2 | Anti-first-pass effect compounds | BIOAVAILABILITY SYSTEMS, L.L.C. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576123-B2 | Anti-first-pass effect compounds | BIOAVAILABILITY SYSTEMS, L.L.C. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7514572-B2 | Anti-first-pass effect compounds | BIOAVAILABILITY SYSTEMS, LLC (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514572-B2 | Anti-first-pass effect compounds | BIOAVAILABILITY SYSTEMS, LLC (US) | 2009-04-07 | — | — | US | disclosed |
| US-20090011013-A1 | Tacrolimus Combination Products | LIFECYCLE PHARMA A/S (DK) | 2009-01-08 | — | — | US | disclosed |
| US-7378534-B2 | Anti-first-pass effect compounds | BIOAVAILABILITY SYSTEMS, LLC. (US) | 2008-05-27 | — | — | US | disclosed |
| US-20080103194-A1 | ANTI-FIRST-PASS EFFECT COMPOUNDS | BIOAVAILABILITY SYSTEMS, LLC (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080103194-A1 | ANTI-FIRST-PASS EFFECT COMPOUNDS | BIOAVAILABILITY SYSTEMS, LLC (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080039520-A1 | ANTI-FIRST-PASS EFFECT COMPOUNDS | BIOAVAILABILITY SYSTEMS, LLC (US) | 2008-02-14 | — | — | US | disclosed |
| US-20080039520-A1 | ANTI-FIRST-PASS EFFECT COMPOUNDS | BIOAVAILABILITY SYSTEMS, LLC (US) | 2008-02-14 | — | — | US | disclosed |
| US-20070244188-A1 | ANTI-FIRST-PASS EFFECT COMPOUNDS | BIOAVAILABILITY SYSTEMS, LLC (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244188-A1 | ANTI-FIRST-PASS EFFECT COMPOUNDS | BIOAVAILABILITY SYSTEMS, LLC (US) | 2007-10-18 | — | — | US | disclosed |
| US-7230027-B2 | Anti-first-pass effect compounds | BIOAVAILABILITY SYSTEMS, L.L.C. (US) | 2007-06-12 | — | — | US | disclosed |
| US-7230027-B2 | Anti-first-pass effect compounds | BIOAVAILABILITY SYSTEMS, L.L.C. (US) | 2007-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090011013-A1 | Tacrolimus Combination Products | CYP2D6, CYP2B6, CYP3A5 | CYP3A4 12/4885TDP1 1912/4885KDM4E 3863/4885 |
| US-20080103194-A1 | ANTI-FIRST-PASS EFFECT COMPOUNDS | ABCG2, FABP2, SLC18A3 | CYP3A4 45/4885TDP1 966/4885KDM4E 3899/4885 |
| US-20070244188-A1 | ANTI-FIRST-PASS EFFECT COMPOUNDS | FABP2, ABCG2, NPSR1 | CYP3A4 327/4885TDP1 2553/4885KDM4E 3978/4885 |
| US-20080039520-A1 | ANTI-FIRST-PASS EFFECT COMPOUNDS | ABCG2, FABP2, HDLBP | CYP3A4 19/4885TDP1 790/4885KDM4E 3550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.